par Stewart, A Keith;Rajkumar, Vincent SV;Dimopoulos, Meletios Athanassios;Masszi, Tamás;Špička, Ivan;Oriol, Albert;Hájek, Roman;Rosiñol, Laura;Siegel, David D.A.;Mihaylov, Georgi GG;Goranova-Marinova, Vesselina;Rajnics, Péter;Suvorov, Aleksandr;Niesvizky, Ruben;Jakubowiak, Andrzej AJ;San-Miguel, Jesus;Ludwig, Heinz;Wang, Michael;Maisnar, Vladimír;Minarik, Jiri;Bensinger, William WI;Mateos, Maria-Victoria;Ben Yehuda, Dina;Kukreti, Vishal;Zojwalla, Naseem;Tonda, Margaret E;Yang, Xinqun;Xing, Biao;Moreau, Philippe;Palumbo, Antonio;Meuleman, Nathalie 
; [et al.]
Référence The New England journal of medicine, 372, 2, page (142-152)
Publication Publié, 2015-01
; [et al.]Référence The New England journal of medicine, 372, 2, page (142-152)
Publication Publié, 2015-01
Article révisé par les pairs
| Résumé : | Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. |
